Patent · US Active

DLL3 single domain antibodies and therapeutic compositions thereof

US12365728B2 · kind B2 · utility

0Cited by

37References

32Claims

0Family size

Assignee

Inhibrx Biosciences, Inc. · US

Inventors

Brendan P. Eckelman · Village of La Jolla, US
Michael D. KAPLAN · Boynton Beach, US
Katelyn M. Willis · Village of La Jolla, US
Rajay Pandit · Village of La Jolla, US
Angelica Sanabria · Village of La Jolla, US
Sydney A. Barnes · Village of La Jolla, US
Margaret E. Haerr · Village of La Jolla, US
John C. Timmer · Village of La Jolla, US

Key dates

Filing date	Oct 9, 2019
Grant date	Jul 22, 2025
Priority date	—
Expiry date	Oct 6, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific contracts and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.